Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth I Buchbinder

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
Hematology/Oncology Clinics of North America|March 24, 2021
Immune Checkpoint Therapies for MelanomaElizabeth I Buchbinder
American Journal of Clinical Oncology|November 13, 2015
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their InhibitionElizabeth I Buchbinder, Anupam Desai
American Journal of Clinical Dermatology|January 28, 2025
Individualized Neoantigen-Directed Melanoma TherapyKaram Khaddour, Elizabeth I Buchbinder
Cancers|December 24, 2021
Cancer Therapy Targeting CD47/SIRPαNazli Dizman, Elizabeth I Buchbinder
Cancer Journal (Sudbury, Mass.)|March 25, 2024
Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?Julie Fishman, Elizabeth I Buchbinder
Nature Reviews. Clinical Oncology|January 21, 2016
Melanoma in 2015: Immune-checkpoint blockade - durable cancer controlElizabeth I Buchbinder, F Stephen Hodi
Trends in Cancer|July 26, 2017
Biomarkers in Melanoma: Lessons from Translational MedicineElizabeth I Buchbinder, Keith T Flaherty
Current Oncology Reports|November 27, 2019
The Evolution of Adjuvant Therapy for MelanomaJustine V Cohen, Elizabeth I Buchbinder
Hematology/Oncology Clinics of North America|March 6, 2019
Immunotherapy ToxicityCharlene M Mantia, Elizabeth I Buchbinder
Clinical Therapeutics|March 10, 2015
Cytotoxic T-lymphocyte antigen-4 blockade in melanomaElizabeth I Buchbinder, David F McDermott
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
Hematology/Oncology Clinics of North America|March 24, 2021
Immune Checkpoint Therapies for MelanomaElizabeth I Buchbinder
American Journal of Clinical Oncology|November 13, 2015
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their InhibitionElizabeth I Buchbinder, Anupam Desai
American Journal of Clinical Dermatology|January 28, 2025
Individualized Neoantigen-Directed Melanoma TherapyKaram Khaddour, Elizabeth I Buchbinder
Cancers|December 24, 2021
Cancer Therapy Targeting CD47/SIRPαNazli Dizman, Elizabeth I Buchbinder
Cancer Journal (Sudbury, Mass.)|March 25, 2024
Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?Julie Fishman, Elizabeth I Buchbinder
Nature Reviews. Clinical Oncology|January 21, 2016
Melanoma in 2015: Immune-checkpoint blockade - durable cancer controlElizabeth I Buchbinder, F Stephen Hodi
Trends in Cancer|July 26, 2017
Biomarkers in Melanoma: Lessons from Translational MedicineElizabeth I Buchbinder, Keith T Flaherty
Current Oncology Reports|November 27, 2019
The Evolution of Adjuvant Therapy for MelanomaJustine V Cohen, Elizabeth I Buchbinder
Hematology/Oncology Clinics of North America|March 6, 2019
Immunotherapy ToxicityCharlene M Mantia, Elizabeth I Buchbinder
Clinical Therapeutics|March 10, 2015
Cytotoxic T-lymphocyte antigen-4 blockade in melanomaElizabeth I Buchbinder, David F McDermott
Pageof 9